Patents Assigned to Oncolytics Biotech, Inc.
  • Publication number: 20200237917
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Application
    Filed: February 13, 2020
    Publication date: July 30, 2020
    Applicant: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 10167452
    Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: January 1, 2019
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 10039827
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: August 7, 2018
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 9610309
    Abstract: Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: April 4, 2017
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Patent number: 9610352
    Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 4, 2017
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Patent number: 9365823
    Abstract: The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: June 14, 2016
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Publication number: 20150224198
    Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Patent number: 9044498
    Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 2, 2015
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Patent number: 9045728
    Abstract: Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 2, 2015
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Publication number: 20140186301
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Application
    Filed: February 13, 2014
    Publication date: July 3, 2014
    Applicant: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Publication number: 20140178969
    Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 26, 2014
    Applicant: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 8709443
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 29, 2014
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Patent number: 8691241
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: April 8, 2014
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C Coffey
  • Patent number: 8685734
    Abstract: The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: April 1, 2014
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 8658158
    Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: February 25, 2014
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Bradley G. Thompson
  • Patent number: 8512712
    Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: August 20, 2013
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Patent number: 8491886
    Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: July 23, 2013
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Bradley G. Thompson
  • Patent number: 8491884
    Abstract: The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: July 23, 2013
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Patent number: 8470312
    Abstract: Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: June 25, 2013
    Assignee: Oncolytics Biotech, Inc.
    Inventors: Matthew C. Coffey, Bradley G. Thompson, Hardev Pandha
  • Patent number: 8298785
    Abstract: The present invention provides a method of detecting adventitious agents in a composition comprising a microorganism by using ribozyme-expressing indicator cells, as well as indicator cells useful in such detection.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: October 30, 2012
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey